Quarterly report pursuant to Section 13 or 15(d)

Statements of Cash Flows - Non-Cash Activities (Unaudited) (Parenthetical)

v3.24.3
Statements of Cash Flows - Non-Cash Activities (Unaudited) (Parenthetical) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Supplemental disclosure of noncash activities related to the uBriGene Repurchase Transaction (see Note 5):    
Fair value of assets received $ 2,209 $ 0
Fair value of supplies received expensed to research and development 2,509 0
Accounts receivable written off (6,967) 0
Accounts payable written off 3,644 0
Deferred purchase consideration $ (1,295) $ 0